基因和转录基因变化导致了5-甲抗性HCT116细胞的攻击性
Pornchai Sooksaen1, Arthid Thim-Uam2, Ratsada Praphasawat1
1Department of Pathology, School of Medicine, University of Phayao, Phayao, 56000, Thailand.
Medical oncology (Northwood, London, England)
|October 10, 2025
概括
对5-甲 (5-FU) 耐药的结肠直肠癌细胞显示出增加的攻击性和侵入性. 这种抗性与特定的基因和非编码RNA变化有关,可能涉及PI3K-AKT通路.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 5-甲 (5-FU) 耐药性是结肠直肠癌 (CRC) 治疗的一个主要挑战.
- 遗传因素有助于化学抵抗,瘤复发和增加癌症的攻击性.
研究的目的:
- 为了表征5-FU抗性CRC细胞的转录组形状.
- 了解CRC中抗化学性和侵略性瘤行为的基础分子机制.
主要方法:
- 通过逐渐暴露于药物,诱导HCT116结肠癌细胞中的5-FU耐药性.
- 使用MTT,克隆基因和划痕试验评估化学抗性和侵入性.
- 通过下一代测序 (NGS) 进行转录基因分析.
主要成果:
- 抗5-FU的细胞表现出交叉抗性和增强的侵入性,具有上调的矩阵金属蛋白酶 (MMP-2,MMP-9).
- 观察到T细胞免疫受体与Ig和ITIM域 (TIGIT) 和细胞粘附基因 (NXPE1,NCAM1) 的过度表达.
- 确定了特定微RNAs (miR-6789,miR-5006,miR-7107) 的升级调节和PI3K-AKT通路的激活.
结论:
- 对5-FU抗性CRC细胞的转录基因变化与侵略性表型有关.
- 上调基因和非编码RNA,可能通过PI3K-AKT通路,有助于化学抵抗和侵入性.
- 这些发现为开发新疗法以克服CRC中5-FU耐药性的潜在目标提供了潜在的目标.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K